19 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2.
Bayer Pharma
Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2.
Abbvie
Selective inhibitors of protein methyltransferases.
Icahn School of Medicine At Mount Sinai
Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8.
University of North Carolina At Chapel Hill
Positioning of an unprecedented 1,5-oxaza spiroquinone scaffold into SMYD2 inhibitors in epigenetic space.
Gachon University
Protein Lysine Methyltransferase SMYD2: A Promising Small Molecule Target for Cancer Therapy.
Zhejiang University
HIV latency reversal agents: A potential path for functional cure?
S£O Paulo State University (Unesp)
Synthesis and structure-activity relationship studies of LLY-507 analogues as SMYD2 inhibitors.
Key Laboratory of Molecule Synthesis and Function Discovery (Fujian Province University)
Design, Synthesis, and Biological Activity of Substrate Competitive SMYD2 Inhibitors.
Astrazeneca
Histone methyl transferases: A class of epigenetic opportunities to counter uncontrolled cell proliferation.
Punjabi University
Selective, Small-Molecule Co-Factor Binding Site Inhibition of a Su(var)3-9, Enhancer of Zeste, Trithorax Domain Containing Lysine Methyltransferase.
Pfizer
Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor.
Epizyme
Discovery of Bisubstrate Inhibitors of Nicotinamide N-Methyltransferase (NNMT).
Icahn School of Medicine At Mount Sinai
Discovery of phenyl acetic acid substituted quinolines as novel liver X receptor agonists for the treatment of atherosclerosis.
Wyeth Research